23 min listen
Extending Precision Medicine Beyond Cancer
FromThe Bio Report
ratings:
Length:
33 minutes
Released:
Oct 15, 2020
Format:
Podcast episode
Description
While the potential for precision medicine has excited drug developers and clinicians with the promise of delivering more meaningful therapies to patients, the advent of these medicines has largely come in the area of cancer. As the understanding of the biology of other diseases is better understood, efforts to develop precision medicines are advancing into new areas. We spoke to Rachel Laing, managing director of the life sciences consulting firm Bionest, about the state of precision medicine, what can be learned from the experience in cancer, and what it will take to make precision medicine approaches the way we treat diseases broadly.
Released:
Oct 15, 2020
Format:
Podcast episode
Titles in the series (100)
The Lean Startup Takes Hold in the Life Sciences: The National Science Foundation and the National Institutes of Health, concerned about seeing the science they fund commercialized, have embraced the Lean Startup method as a way to improve the odds of success for new companies. Steve Blank, whose wo... by The Bio Report